Endocrinology, Vol 110, 214-219, Copyright © 1982 by Endocrine Society

ARTICLES

The antiandrogenic effects of delta 1-testolactone (Teslac) in vivo in rats and in vitro in human cultured fibroblasts, rat mammary carcinoma cells, and rat prostate cytosol

RA Vigersky, D Mozingo, C Eil, V Purohit and J Bruton

The antiandrogenic properties of delta 1-testolactone (17 alpha-oxa-D- homo-1,4-androstane-3,17-dione; Teslac) were investigated in vivo and in vitro. Teslac (75 mg/day for 7 days) inhibited the rise in ventral prostate weight induced by testosterone (T) (P less than 0.001), dihydrotestosterone (DHT) (P less than 0.05), and a combination of T plus 17 beta-estradiol (E2) (P less than 0.01) in immature castrate rats. Similar effects were seen on the seminal vesicles after T and T plus E2 (P less than 0.001). Teslac also decreased prostate and seminal vesicle weights in intact immature rats. The effects of Teslac were dose and time dependent. Teslac did not change the concentration of serum T or DHT. However, Teslac inhibited DHT binding to the androgen receptor (Ki = 2.5 +/- 0.8 X 10(-7) M) in cytosol of the rat prostate. Teslac also inhibited DHT binding to the androgen receptor in cultured human prepuce fibroblasts and cultured rat mammary tumor cells (Ki = 1.9 +/- 0.3 X 10(-5) M). The results indicate that Teslac, in addition to its antiaromatase activity, is an antiandrogen by virtue of its interaction with the androgen receptor.

This article has been cited by other articles:

				N. Pitteloud, A. A. Dwyer, S. DeCruz, H. Lee, P. A. Boepple, W. F. Crowley Jr., and F. J. Hayes Inhibition of Luteinizing Hormone Secretion by Testosterone in Men Requires Aromatization for Its Pituitary But Not Its Hypothalamic Effects: Evidence from the Tandem Study of Normal and Gonadotropin-Releasing Hormone-Deficient Men J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 784 - 791. [Abstract] [Full Text] [PDF]

				J. D. Veldhuis and A. Iranmanesh Short-Term Aromatase-Enzyme Blockade Unmasks Impaired Feedback Adaptations in Luteinizing Hormone and Testosterone Secretion in Older Men J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 211 - 218. [Abstract] [Full Text] [PDF]

				A. M. Vinggaard, C. Nellemann, M. Dalgaard, E. B. Jorgensen, and H. R. Andersen Antiandrogenic Effects in Vitro and in Vivo of the Fungicide Prochloraz Toxicol. Sci., October 1, 2002; 69(2): 344 - 353. [Abstract] [Full Text] [PDF]

				M. S. Marty, J. W. Crissman, and E. W. Carney Evaluation of the Male Pubertal Onset Assay to Detect Testosterone and Steroid Biosynthesis Inhibitors in CD Rats Toxicol. Sci., April 1, 2001; 60(2): 285 - 295. [Abstract] [Full Text] [PDF]

				F. J. Hayes, S. DeCruz, S. B. Seminara, P. A. Boepple, and W. F. Crowley Jr. Differential Regulation of Gonadotropin Secretion by Testosterone in the Human Male: Absence of a Negative Feedback Effect of Testosterone on Follicle-Stimulating Hormone Secretion J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 53 - 58. [Abstract] [Full Text]

				F. J. Hayes, S. B. Seminara, S. DeCruz, P. A. Boepple, and W. F. Crowley Jr. Aromatase Inhibition in the Human Male Reveals a Hypothalamic Site of Estrogen Feedback J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3027 - 3035. [Abstract] [Full Text]

				E. A. Cummings, S. R. Salisbury, M. L. Givner, and R. S. Rittmaster Testolactone-Associated High Androgen Levels, a Pharmacologic Effect or a Laboratory Artifact? J. Clin. Endocrinol. Metab., March 1, 1998; 83(3): 784 - 787. [Abstract] [Full Text]